Pharmacological Exposure and the Development of Drug Resistance in HIV

Murphy S.L. Deaths: final data for 1998. National Vital Statistics Report 2000; 48: 1–105.

Nash D. , Fordyce E.J. , Singh T. , & Forlenza S. Trends in mortality rates among reported Acquired Immune Deficiency (AIDS) case patients in New York City, 1990–1998. XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 3385.

Palella F.J. , Delaney K.M. , Moorman A.C. , Loveless M.O. , Fuhrer J. , Satten G.A. , Aschman D.J. , & Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338: 853–860.

AVANTI Steering Committee. Analysis of HIV-1 clinical trials: statistical magic? Lancet 1999; 353: 2061–2064.

Ledergerber B. , Egger M. , Opravil M. , Telenti A. , Hirschel B. , Battegay M. , Vernazza P. , Sudre P. , Flepp M. , Furrer H. , Francioli P. , & Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863–868.

Wit F.W. , van Leewen R. , Weverling G.J. , Nauta K. , Steingrover R. , Schuijtemaker J. , Eyssen X. , Fortuin D. , Weeda M. , de Wolf F. , Reiss P. , Danner S.A. , & Lange J.M. Outcome and predictors of failure of highly active anti-retroviral therapy: one year follow-up of a cohort of human immunodeficiency type-1-infected persons. Journal of Infectious Diseases 1999; 179: 790–798.

Yamashita T. Effect of prior treatment and host genotype on response to highly active antiretroviral therapy in the multicenter AIDS cohort study (MACS). XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 4089.

Andreoni M. , Sarmati L. , Nicastri E. Discordance between genotypic and phenotypic drug resistance in HIV-1 seropositive patients treated with two nucleoside analogues. XIII International AIDS Conference. Durban, South Africa, 9–14 July, 2000; Abstract 3290.

Condra J.H. , Petropoulous C.J. , Ziermann R. , Schleif W.A. , Shivaprakash M. , & Emini E.A. Drug resistance and predicted virological responses to human immunodeficiency virus type 1 protease inhibitor therapy. Journal of Infectious Diseases 2000; 182: 758–765.

Weinstock H. , Zaidi I. , Repress R. , Heine W. , Luo C-C , Woods T. , Hellmann N. , Lie Y. , & Kaplan J. Genotypic and phenotypic evidence of antiretroviral drug resistance among drug-naive persons recently diagnosed with HIV-1, USA, 1997–1999. Antiviral Therapy 2000; 5 (Suppl. 3): 345–350.

Crowe S.M. , & Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. Journal of Leukocyte Biology 2000; 68: 345–350.

Venturi G. , Catucci M. , Romano L. , Corsi P. , Leoncini F. , Valensin P.E. , & Zazzi M. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. Journal of Infectious Diseases 2000; 181: 740–745.

Acosta E.P. , Kakuda T.N. , Brundage R.C. , Anderson P.L. , & Fletcher C.V. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases 2000; 30: S151–S159.

Burger D.M. , Meenhoorst P.L. , & Beijen J.H. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Pharmaceutical World Science 1995; 17: 25–30.

Gerber J.G. Using pharmacokinetics to optimize antiretroviral drug–drug interactions in the treatment of human immunodeficiency virus infection. Clinical Infectious Diseases 2000; 30: S123–S129.

Casado J.L. , Dronda F. , Antela A. Pharmacokinetics of the combination of nevirapine, nelfinavir and saquinavirhgc in HIV-infected patients (NELSANE study). XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 3304.

Hogg R. , Yip B. , Chan K. , & Shaughnessy Montaner J. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. XIII International AIDS Conference. Durban, South Africa, 9–14 July, 2000; Abstract 419.

Ruiz L. , Nijhuis M. , Boucher C. , Puig T. , Bonjoch A. , Martinez-Picado J. , Marfil S. , de Jong D. , Burger D. , Arno A. , Balague M. , & Clotet B. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndrome and Human Retroviruses 1998; 19: 19–28.

Hsu A. , Williams L. , Chiu Y-L , Hill L. , McMillan F. , Lamm J. , Rynkiewicz K. , Foit C. , Ji Q. , Hutman W. , Ryan J. , Sun E. , & Japour A. Pharmacokinetic (PK) interactions between ritonavir (RTV) and amprenavir (APV) in healthy volunteers. XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 546.

Lamotte C. , Duval X. , Peytavin G. , & Farinotti R. Amprenavir (APV) plasma concentrations are dramatically increased by association with ritonavir (RTV) baby-doses in HIV-infected patients (pts): possible combination with efavirenz (EFV). XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 4123.

Moreno A. , Casado J.L. , Marte-Belda P. Efficacy of the combination of ritonavir plus indinavir plus a non-nucleoside reverse transcriptase inhibitor in patients failing multiple antiretroviral regimens: pharmacokinetic and resistance data (NIVELPROT study). XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 4159.

Zolopa A.R. , Shulman N. , Havlir D. , Gallant J. , Race E. , Jiang P. , Lamn J. , Renz C. , Kempf D. , Hsu A. , & Sun E. Ritonavir intensification of indinavir-containing antiretroviral regimens: the effect of increasing indinavir trough concentration and protease resistance on virological response. Antiviral Therapy 2000; 5 (Suppl. 3): 75.

Saag M.S. , Kilby M. , Ehrensing E. Modulation of saquinavir steady-state pharmacokinetics with ‘baby’ doses of ritonavir in healthy volunteers. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, Portugal, 23–27 October, 1999; Abstract 829.

Kepler T.B. , & Perelson A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proceedings of the National Academy of Science, USA 1998; 95: 11514–11519.

Hoetelmans R.M. , Burger D.M. , Meenhoorst P.L. , & Beijen J.H. Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships. Clinical Pharmacokinetics 1996; 30: 314–327.

Acosta E.P. , Henry K. , Baken L. , Page L.M. , & Fletcher C.V. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708–712.

Inaba T. , Fischer N.E. , Riddick D.S. , Stewart D.J. , & Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicology Letters 1997; 93: 215–219.

Back D.J. , Gibbons S.E. , Khoo S.H. , Merry C. , Barry M.G. , & Mulcahy F. Therapeutic drug monitoring of antiretrovirals: Ready for the clinic? Diagnostic Technologies in the Management of HIV/AIDS and Other Life-Threatening Coinfectious Diseases: An IAPAC Symposium, Vienna, Austria, 10 October, 1999; Abstract. http://www.aegis.com/pubs/iapac/2000/IA000201.html.

Hoetelmans R. How will HIV therapeutic drug monitoring be used in clinical settings? 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Calif., USA, 26–29 September, 2000; Abstract 1172.

Hirsch M.S. , Brun-Vezinet F. , D'Aquila R.T. , Hammer S.M. , Johnson V.A. , Kuritzkes D.R. , Loveday C. , Mellors J.W. , Clotet B. , Conway B. , Demeter L.M. , Vella S. , Jacobsen D.M. , & Richman D.D. Antiretroviral drug resistance testing in adult with HIV infection. Recommendations of an International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283: 2417–2426.

Bean P. PMGFAD. Therapeutic drug monitoring of anti-retroviral agents. American Clinical Laboratories 2000; 19: 20–22.

Hoetelmans R.M. Sanctuary sites in HIV-1 infection. Antiviral Therapy 1998; 3: 13–15.

Piscitelli S.C. The limited value of therapeutic drug monitoring in HIV infection. Medscape HIV/AIDS 1999; 5. http://hiv.medscape.com/Medscape/HIV/journal/1999/v05.n04/mha0803/mha0803.pisc/mha0803.pisc-01.html.

Hill A. , Craig C. , & Whittaker L. Prediction of drug potency from C_min/IC₅₀ or C_min/IC₉₅ ratio: false precision. Antiviral Therapy 2000; 5 (Suppl. 3): 50.

van Heeswijk R.P. , Veldkamp A.I. , Mulder J.W. , Meenhorst P.L. , Wit F.W. , Lange J.M. , Danner S.A. , Foudraine N.A. , Kwakkelstein M.O. , Reiss P. , Beijnen J.H. , & Hoetelmans R.M. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14: F77–F82.

Kempf D. , Hsu A. , Jian P. , Rode R. , Hertogs K. , Larder B. , Zolopa A. , Shulman N. , Havlir D. , Gallant J. , Race E. , Boller S. , Swerdlow J. , Jasinsky O. , Renz C. , & Sun E. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4–8 February, 2001; Abstract 523.

Larder B. , Kemp S.D. , & Hertogs K. Quantitative prediction of HIV-1 phenotypic resistance from genotypes: the virtual phenotype (Virtual Phenotype). Antiviral Therapy 2000; 5: 49.

AIDS Clinical Trials Group Pharmacology Committee. Position paper on therapeutic drug monitoring for anti-retroviral drugs: Using drug concentrations to guide individual therapy. 1998. http://www.hopkins-aids.edu/publications/report/jan00_4.html.

Pozniak A. , Gazzard B.G. , Babiker A. , Back D. , Deutsch J. , Churchill D. , Fisher M. , Johnson M. , Loveday C. , Main J. , Moyle G. , Nelson M. , Peters B. , Philips A. , Pillay D. , Poppa A. , Taylor C. , Williams I. , & Youle M. British HIV Association Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 1999. http://www.aidsmap.com/about/bhiva/bhivagd.asp.

Mayers D. Both antiretroviral drug levels and drug resistance are associated with short-term virologic responses to subsequent drug regimens in CPCRA 046 (GART study). 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 8–11 July, 2001; Abstract 124.

Clevenbergh P. , Durant J. , Garraffo R. , Kirstetter M. , Daures J.P. , & Infectio-SUD Group. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentric randomized controlled trial: 12 weeks results. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, Abstract 260B. Chicago, Ill., USA, 4–8 February, 2001; Abstract 260B.

Burger D. , Hugen P. , Droste J. , & Huitema A. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: results from Athena. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 8–11 July, 2001; Abstract 30.

Acosta E.P. The promise of therapeutic drug monitoring in HIV infection. Medscape HIV/AIDS 1999; 5. http://hiv.medscape.com/Medscape/HIV/journal/1999/v05.n04/mha0803/mha0803.acos/mha0803.acos-01.html.

Peter K. , & Gambertoglio J.G. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection. Pharmaceutical Research 1998; 15: 819–825.

Stetcher B.N. , Pesce A.J. , Hurtubise P.E. , & Frame P.T. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Therapeutic Drug Monitoring 1992; 14: 281–285.

Stretcher B.N. , Pescue A.J. , Murray J.A. , Hurtubise P.E. , Vine W.H. , & Frame P.T. Concentrations of phosphorylated zidovudine (ZDV) in patients leukocytes do not correlate with ZDV dose or plasma concentrations. Therapeutic Drug Monitoring 1991; 13: 325–331.

Hoetelmans R.M. , Meehorst P.L. , Mulder J.W. , Burger D.M. , Koks C.H. , & Beijnen J.H. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir and ritonavir. Pharmaceutical World Science 1997; 19: 159–175.

Stein D.S. , Fish D.G. , Biello J.A. , Preston S.L. , Martineau G.L. , & Drusano G.L. A 24-week, open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10: 485–492.

Burger D.M. , Hoetelmans R.M. , Hugen P.W. , Mulder J.W. , Meenhorst P.L. , Koopmans P.P. , Brinkman K. , Keuter M. , Dolmans W. , & Hekster Y.A. Low plasma concentrations of indinavir are related to virological failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998; 3: 215–220.

Hoetelmans R.M. , Reijers M.H. , Weverling G.J. , ten Kate R.W. , Wit F.W. , Mulder J.W. , Weigel H.M. , Frissen P.H. , Roos M. , Jurriaans S. , Schuitemaker H. , De Wolf F. , Beijnen J.H. , & Lange J.M. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12: F111–F115.

Harris M. , Durakovic C. , Rae S. , Raboud J. , Fransen S. , Shillington A. , Conway B. , & Montaner J.S. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. Journal of Infectious Diseases 1998; 177: 1514–1520.

Murphy R.L. , Sommadossi J.P. , Lamson M. , Hall D.B. , Myers M. , & Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type1. Journal of Infectious Diseases 1999; 179: 1116–1123.

Fletcher C.V. , Brundage R.C. , Remmel R. P. , Page L.M. , Weller D. , Calles N.R. , Simon C. , & Kline M.W. Pharmacologic characteristics of indinavir, didanosine and stavudine in human immunodefificiency virus-infected children receiving combination therapy. Antimicrobial Agents & Chemotherapy 2000; 44: 1029–1034.

Dieleman J. , Gyssens I. , van der Ende M. , de Marie S. , & Burger D.M. Urological complaints in relation to indinivir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473–478.

Dieleman J. , van Rossum A-M , van der Ende M. High prevalence of subclinical nephrotoxicity with indinavir. XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 4264.

Schapiro J.M. , Winters M.A. , Stewart F. , Efron B. , Norris J. , Kozal M.J. , & Merigan T.C. The effect of high-dose saquinavir on viral load an CD4+ T-cell counts in HIV-infected patients. Annals of Internal Medicine 1996; 124: 1039–1050.

Danner S.A. , Carr A. , Leonard J.M. , Lehman L.M. , Gudiol F. , Gonzales J. , Raventos A. , Rubio R. , Bouza E. , Pintado V. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. New England Journal of Medicine 1995; 333: 1528–1533.

Burger D.M. , Hugen P.W.H. , Aanoutse R.E. , & Hoetelmans RM on behalf of the ATHENA Study Group. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. AIDS 2000; 13: S89.

Durant J. , Clevenbergh P. , Garraffo R. , Halfon P. , Icard S. , del Giudice P. , Montagne N. , Schapiro J.M. , & Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS 2000; 14: 1333–1339.

Meaden E.R. , Brown R.A. , Hoggard , Maher B. , Khoo S.H. , & Back D.J. Decreased P-glycoprotein but unaltered multidrug resistance-associated protein in HIV patients. AIDS 2000; 14: S94.

Huisman M.T. , Smit J.W. , Hoetelmans R.M.W. , Wiltshire R. , Beijnen J.H. , & Schinkel H. The role of P-glycoprotein in oral bioavailability, brain and fetal penetration of the HIV protease inhibitor saquinavir. AIDS 2000; 14 (Suppl. 4): S94.

Hennessy M. , Clarke S. , Mulcahny , Bergin C. , Tija J. , Back D. , & Barry M. Intracellular pharmacokinetics in HIV positive patients. AIDS 2000; 14 (Suppl. 4): S97.

Choo E.F. , Leake B. , Wandel C. , Imamura H. , Wood A.J. , Wilkinson G.R. , & Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1protease inhibitors into brain and testis. Drug Metabolism Disposition 2000; 28: 655–660.

Kim R.B. , Fromm M.F. , Wandel C. , Leake B. , Wood A.J. , Roden D.M. , & Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation 1998; 101: 289–294.

Cameron D.W. , Japour A.J. , Xu Y. , Hsu A. , Mellors J. , Farthing C. , Cohen C. , Poretz D. , Markowitz M. , Follansbee S. , Angel J.B. , McMahon D. , Ho D. , Devanarayan V. , Rode R. , Salgo M. , Kempf D.J. , Granneman R. , Leonard J.M. , & Sun E. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13: 213–224.

Saah A. , Winchell G. , Senuik M. , Mehota D. , & Deutsch P. Multiple-dose pharmacokinetics(PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 21 January – 4 February, 2000; Abstract 362.

Sham H.L. , Kempf D.J. , Molla A. , Marsh K.C. , Kumar G.N. , Chen C.M. , Kati W. , Stewart K. , Lal R. , Hsu A. , Betebenner D. , Korneyeva M. , Vasavanonda S. , McDonald E. , Saldivar A. , Wideburg N. , Chen X. , Niu P. , Park C. , Jayanti V. , Grabowski B. , Granneman G.R. , Sun E. , Japour A.J. , & Norbeck D.W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents & Chemotherapy 1998; 42: 3218–3224.

Gatell J.M. , Lange J. , Arnaiz J.A. , Faetkenheuer G. , Mallolas J. , & Clotet B. A randomized study comparing continued indinavir (800 mg tid) to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleosides analogues. The bid efficacy and safety trial (BEST). XIII International AIDS Conference, Durban, South Africa, 9–14 July, 2000; Abstract 484.

Joshi A.S. , Barrett J.S. , Fiske W.D. Population pharmacokinetics of efavirenz in Phase II studies and relationship with efficacy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Calif., USA, 26–29 September; Abstract 1201.

Marzolini C. , Telenti A. , Decosterd L.A. , Greub G. , Biollaz J. , & Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71–75.

Havlir D. , Cheeseman S.H. , McLaughlin M. , Murphy R. , Erice A. , Spector S.A. , Greenough T.C. , Sullivan J.L. , Hall D. , Myers M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 1995; 171: 537–545.

Montaner J.S. , Reiss P. , Cooper D. , Vella S. , Harris M. , Conway B. , Wainberg M.A. , Smith D. , Robinson P. , Hall D. , Myers M. , & Lange J.M. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada and Australia Study. Journal of the American Medical Association 1998; 279: 930–937.